Microsoft word - vivit-publikationsliste bis 03 2010.doc

Publikationsliste VIVIT-Institut
ORIGINALPUBLIKATIONEN 2010 – 1997
112. Rein P, Saely CH, Muendlein A, Vonbank A, Drexel H. Serial Decline of Kidney Function as a Novel Biomarker for the Progression of Atherothrombotic Disease. Atherosclerosis 2010 (in press). 111.Saely CH, Eber B, Pfeiffer KP, Drexel H. Low Serum LDL Cholesterol in Patients With Type 2 Diabetes: An Analysis on Two Different Patient Populations. Int J Cardiol 2010 (in press). 110. Saely CH, Rein P, Vonbank A, Drexel H. Serum Levels of C-Reactive Protein in Patients With Stable Coronary Artery Disease: JUPITER in Perspective. Int J Cardiol 2010 (in press). 109.Rein P, Beer S, Saely CH, Vonbank A, Drexel H. Prevalence of impaired glucose metabolism in individuals with peripheral arterial disease. Int J Cardiol 2010 (in press). 108.Beer S, Saely CH, Hoefle G, Rein P, Vonbank A, Breuss J, Gaensbacher B, Muendlein A, Drexel H. Low Bone mineral density is not associated with angiographically determined atherosclerosis in men. Osteoporosis International 2010 (in press). 107. Saely CH, Aczel S, Koch L, Schmid F, Marte T, Huber K, Drexel H. Diabetes as a coronary artery disease risk equivalent: before a change of paradigm? Eur J Cardiovasc Prev Rehabil 2010 2010;17(1):94-9. 106.Drexel H, Aczel S, Marte T, Vonbank A, Saely CH. Factors Predicting Cardiovascular Events in Statin-Treated Diabetic and Non-Diabetic Patients With Coronary Atherosclerosis. Atherosclerosis 2010; 208:484-489. 105.Aschner P., Katzeff H.L., Guo H., Sunga S., Williams-Herman D., Kaufman K.D, Goldstein B.J. for the Sitagliptin Study 049 Group. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism 2010;1:252-61. 104.Biebl A, Muendlein A, Kazakbaeva Z, Heuberger S, Sonderegger G, Drexel H, Lau S, Nickel R, Kabesch M, Simma B. CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patients. PLoS One. 2009; 4:e7374. 103. Drexel H. Glukose, Lipide, Blutdruck: Zielwerte beim Typ-2-Diabetes. Universum 102. Drexel H. Herzinsuffizienz und Diabetes. Jatros (Kardiologie und Gefäßmedizin) 101.Drexel H. Herzinsuffizienz und Diabetes. Jatros (Diabetes und Stoffwechsel) 2009; 100. Bochdansky T, Böckelberger M, Laube W, Solti K, Drexel H. Evaluation zweier interdisziplimärer Nachsorgestationen. Phys Med Rehab Kuror 2009; 19:256-265. 99. Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion- exchange resins, omega-3 fatty acids: which drugs for which patients? Fundam Clin Pharmacol 2009; 23:687-692. 98. Saely CH, Risch L, Frey F, Lupi GA, Leuppi JD, Drexel H, Huber AH. Body-Mass- Index, Blood Pressure, and Serum Cholesterol in Young Swiss Men: An Analysis on 56784 Army Conscripts. Swiss Med Weekly 2009; 139:518-524. 97. Muendlein A, Geller-Rhomberg S, Saely CH, Winder T, Sonderegger G, Rein P, Beer S, Vonbank A, Drexel H. Significant impact of chromosomal locus 1p13.3 on serum LDL cholesterol and on angiographically characterized coronary atherosclerosis. Atherosclerosis 2009; 206:494-499. 96. Marte T, Saely CH, Schmid F, Koch L, Drexel H. Effectiveness of atrial fibrillation as an independent predictor of death and coronary events in patients having coronary angiography. Am J Cardiol 2009; 103:36-40. 95. Drexel H, Saely CH. Brauchen alle Hypertoniker ein Statin? Universum Innere 94. Winder T, Scheithauer W, Lang A. Comment on Karapetis et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. N Engl J Med 2009; 360: 834-835. 93. Winder T, Muendlein A, Geller-Rhomberg S, Dirschmid K, Hartmann B, Knauer M, Drexel H, Wenzl E, De Vries, A, Lang A. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. Oncol Rep 2009; 21:1283-1287. 92. Muendlein A, Saely CH, Rhomberg S, Sonderegger G, Loacker S, Rein P, Beer S, Vonbank A, Winder T, Drexel H. Evaluation of the association of genetic variants on the chromosomal loci 9p21.3, 6q25.1, and 2q36.3 with angiographically characterized coronary artery disease. Atherosclerosis 2009; 205: 174-180. 91. Saely CH, Drexel H. Highlights – kardiovaskuläre Prävention. Wiener Medizinische Wochenschrift 2009; Skriptum 07/09:14-16. 90. Drexel H, Saely CH. Lifestyle versus Medikamente. Wiener Medizinische Wochenschrift; Skriptum 07/09:20-22. 89. Drexel H, Saely CH. Fettgewebe – diabetische Dyslipidämie als Schnittpunkt zur Atherosklerose. Wiener Medizinische Wochenschrift; Skriptum12/09: 10-12. 88. Saely CH, Drexel H. Strategien zur Verlangsamung der Atherogenese bei Typ-2- Diabetes. Diabetes Forum 2009; 04:26-27. 87. Saely CH., Drexel H. Statement zum niedrigen LDL-Cholesterin bei Diabetes. 86. Saely CH., Drexel H. Statine bei normalem LDL-Cholesterin. Arzt & Praxis 2009: 63. 85. Saely CH., Drexel H. Residualrisiko bei KHK-Patienten unter Statintherapie. Journal für Vaskuläre Medizin 2009; 03:9-11. 84. Drexel H. Dyslipidämie als Schnittstelle zur Atherosklerose. Wiener Klienische Wochenschrift 2009; Spezial 21-22:4. 83. Winder T, Muendlein A, Gasser K, Lingg G, Walser J, Karner-Hanusch J, Dirschmid, K, Drexel H, Lang A. Challenges and pitfalls in HNPCC: A Pedigree of an Austrian HNPCC Family Beyond four Generations! Memo 2008. 82. Muendlein A, Winder T, Loacker S, Drexel H. Einfluss von DNA-Variationen auf die koronare Herzerkrankung. Journal für Kardiologie 2008. 11-12:342-346. 81. Toplak H, Drexel H, Hoppichler F, Huber K, Ludvik B. Hochdosis-Statintherapie versus zaghafte Lipidintervention. Journal für Vaskuläre Medizin 2008; 2:19-21. 80. Risch L, Saely CH, Drexel H. The medical laboratory in preventive care. Therapeutische Umschau 2008; 65:481-485. 79. Drexel H. Statine bei „normalem LDL-C“. Universum Innere Medizin 6/2008 (ÖGIM- 78. Drexel H. HDL-Cholesterin – ILLUMINATE-Studie, neue Subanalyse. HDL- Cholesterin und KHK. Universum Innere Medizin. 2008:4. 77. Drexel H, Saely CH. Diabetes und metabolisches Syndrom – Kardiovaskuläre Auswirkungen und Therapieoptionen. Wiener Medizinische Wochenschrift 2008: 2. 76. Drexel H & Saely CH. Dyslipidämie und Hyperkoagulabilität. Entscheidend für das kardiovaskuläre Risiko bei Typ-2-Diabetikern. Wiener Medizinische Wochenschrift. Kongressjournal 2007 (anlässlich 35.Jahrestagung der ÖDG). 75. Rein P, Saely CH, Aczel S, Patsch B, Drexel H. Omega-3 Fatty Acids Significantly Reduce Postprandial Triglyceridemia in Male Smokers: A Pilot Study. Nutrition, Metabolism & Cardiovascular Diseases 2009;19:e3-4. 74. Saely CH, Dyballa T, Vonbank A, Woess M, Rein P, Beer S, Jankovic V, Boehnel C, Aczel S, Drexel H. Type 2 Diabetes But Not Coronary Atherosclerosis Is an Independent Determinant of Impaired Mobility in Angiographied Coronary Patients. Diab Res Clin Pract 2008: 82(2):185-189. 73. Saely CH, Vonbank A, Rein P, Woess M, Beer S, Aczel S, Jankovic V, Boehnel C, Risch L, Drexel H. Alanine aminotransferase and gamma-glutamyl transferase are associated with the metabolic syndrome but not with angiographically determined coronary atherosclerosis. Clin Chim Acta 2008: 397 (1-2):82-86. 72. Saely CH, Muendlein A, Vonbank A, Sonderegger G, Aczel S, Rein P, Risch L, Drexel H. Type 2 Diabetes Significantly Modulates the Cardiovascular Risk Conferred by the PAI-1-675 4G/5G Polymorphism in Angiographied Coronary Patients. Clin Chim Acta. 2008; 396:18-22. 71. Saely CH, Drexel H. The Periscope Study. Journal für Kardiologie 2008; 15: 255. 70. Saely CH. Kongressbericht: "Modern Lipid Management". Journal für Kardiologie 69. Drexel H, Saely CH, Langer P, Loruenser G, Marte T, Risch L, Hoefle G, Aczel S. Metabolic and anti-inflammatory benefits of eccentric endurance exercise – a pilot study. Eur J Clin Invest 2008; 38:218-226. 68. Marte T, Saely CH, Schmid F, Koch L, Drexel H. Atrial Fibrillation is a Strong and Independent Predictor of Death and Coronary Events in Angiographied Coronary Patients. Am J Cardiol 2009; 103:36-40. 67. Rhomberg W, Eiter H, Schmid F, Saely CH. Combined Vindesine and Razoxane Shows Antimetastatic Acivitiy in Advanced Soft Tissue Saromas. Clin Exp Metastasis 2008; 25:75-80. 66. Saely CH, Drexel H, Sourij H, Aczel S, Jahnel H, Zweiker R, Langer P, Marte T, Hoefle G, Benzer W, Wascher TC. Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis. An angiographic study. Atherosclerosis 2008; 199:179-186. 65. Muendlein A, Saely CH, Marte T, Schmid F, Koch L, Rein P, Langer P, Aczel S, Drexel H. Synergistic Effects of the Apolipoprotein E 3/ 2/ 4, the Cholesteryl Ester Transfer Protein TaqIB, and the Apolipoprotein C3 -482 C>T Polymorphisms on their Association with Coronary Artery Disease. Atherosclerosis 2008; 199:179-186. 64. Drexel H. Nicotinic acid in the treatment of hyperlipidaemia. Fundam Clin Pharmacol 63. Saely CH, Rein P, Drexel H. The metabolic syndrome and risk of cardiovascular disease and diabetes: experiences with the new diagnostic criteria from the International Diabetes Federation. Horm Metab Res 2007; 39:642-650. 62. Drexel H, Rein P, Hostalek U, Kastelein J. Clinical Experience With Prolonged- Release Nicotinic Acid in Statin-Treated Patients Managed in the Usual-Care Setting in Austria: An Analysis from Niaspan®-Induced HDL-Elevation for Optimizing Risk Control (NEMO) Study. Journal of Clinical and Basic Cardiology 2007;10:7-10. 61. Rhomberg W, Eiter H, Schmid F, Saely CH. Razoxane and Vindesine in Advanced Soft Tissue Sarcomas: Impact on Metastasis, Survival and Radiation Response. Anticanc Res 2007; 27: 3609-3614. 60. Risch L, Saely CH, Hoefle G, Rein P, Langer P, Gouya G, Marte T, Aczel S, Drexel H. Relationship between glomerular filtration rate and the adipokines adiponectin, resistin and leptin in coronary patients with predominantly normal or mildly impaired renal function. Clin Chim Acta 2007;376:108-113. 59. Risch L, Saely CH, Neyer U, Hoefle G, Gouya G, Zerlauth M, Risch GM, Risch M, Drexel H. Prevalence of decreased glomerular filtration rate in patients seeking non-nephrological medical care – an evaluation using IDMS-traceable creatinine based MDRD as well as Mayo Clinic quadratic equation estimates. Clin Chim Acta 2007; 378: 71-77. 58. Hoefle G, Saely CH, Risch L, Koch L, Schmid F, Rein P, Aczel S, Berchtold S, Drexel H. Relationship between the adipose-tissue hormone resistin and coronary artery disease. Clin Chim Acta 2007; 386:1-6. 57. Hoefle G, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P, Drexel H. Leptin, leptin soluble receptor and coronary atherosclerosis. Eur J Clin Invest 2007; 37:629-636. 56. Hoefle G, Muendlein A, Saely CH, Risch L, Rein P, Koch L, Schmid F, Aczel S, Marte T, Langer P, Drexel H. The -11377 C>G promoter variant of the adiponectin gene, prevalence of coronary atherosclerosis, and incidence of vascular events in men. Thromb Haemost 2007; 97:451-457. 55. Saely CH, Risch L, Hoefle G, Rein P, Muendlein A, Marte T, Aczel S, Langer P, Drexel H. Low Serum Adiponectin, the Metabolic Syndrome, and Angiographically Determined Coronary Atherosclerosis. Clin Chim Acta 2007 383:97-102. 54. Drexel H. Reducing risk by raising HDL-cholesterol: the evidence. Eur Heart J 2006; 53. Risch L, Hoefle G, Saely CH, Berchtold S, Drexel H. Evaluation of two fully automated novel enzyme linked immunosorbent assays for the determination of human adiponectin in serum. Clin Chim Acta 2006; 373:121-126. 52. Gouya G, Hartmann G, Fae P, Tauber M, Holzmueller H, Benzer W, Lang A, Schuster A, Drexel H, Offner FA. A case of fulminant post-transplant lymphoproliferative disorder and septicemia. Clin Transplant 2006; 20: 261-264. 51. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H. Lipoprotein(a), Type 2 Diabetes, and Vascular Risk in Coronary Patients. Eur J Clin Invest 2006; 36:91-97. 50. Huber K, Baumgartner H, Darius H, Drexel H, Grimm M, Lang I, Metzler H, Mulac K, Pichler M, Watzke H, Weidinger F, Weihs W, Weltermann A, Wojta J, Zenker G, Christ G. Der Einsatz von Clopidogrel bei Patienten mit akuten Koronarsyndromen, nach perkutaner koronarer Intervention und Stentimplantation. J Kardiol 2006; 13:168-174. 49. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, Hoefle G, Drexel H. ATPIII 2001 But Not IDF 2005 Criteria Of The Metabolic Syndrome Predict Clinical Cardiovascular Events In Subjects Who Underwent Coronary Angiography. Diabetes Care 2006; 29:901-907. 48. Drexel H. Sekundärprävention des akuten Koronarsyndroms. Universum Innere 47. Drexel H. HDL- und LDL-Cholesterin als KHK-Prädiktoren. Diabetes Forum 2005; 46. Drexel H. Neue Argumente und Strategien zur Behandlung des HDL-Cholesterins. J Kardiol 2005; 12[Suppl C]:12-14. 45. Drexel H. Ezetrol: Die Fakten. J Kardiol 2005; 12[Suppl B]: 9-10. 44. European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel: Curr Med Res Opin 2005; 21: 665-682. 43. Drexel H. Modern intervention strategies for managing dyslipidaemia: the case for combination therapy. Br J Diabetes Vasc Dis 2005; 5[Suppl 1]:17-23. 42. Risch L, Drexel H, Huber AR. Differences in glomerular filtration estimates by two cystatin C-based equations. Clin Chem 2005; 51:2211-2212. 41. Risch L, Drexel H, Huber AR. Cystatin C and the risk of death. N Engl J Med 2005; 40. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care 2005; 28:101-107. 39. Hoefle G, Saely CH, Aczel S, Benzer W, Marte T, Langer P, Drexel H. Impact of total and central obesity on vascular mortality in patients undergoing coronary angiography. Int J Obesity 2005; 29:785-791. 38. Saely CH, Aczel S, Marte T, Langer P, Hoefle G, Drexel H. The Metabolic Syndrome, Insulin Resistance, and Cardiovascular Risk in Diabetic and Nondiabetic Patients. J Clin Endocrinol Metab. 2005; 90:5698-5703. 37. Risch L, Saely CH, Reist U, Hefti M, Reist K, Huber AR. Course of glomerular filtration rate markers in patients receiving high dose glucocorticoids following subarachnoidal hemorrhage. Clin Chim Acta 2005; 360:205-207. 36. Drexel H, Aczel S, Marte T, Benzer W, Langer P, Moll W, Saely CH. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol? Diabetes Care. 2005; 28:101-107. 35. Hoefle G, Holzmueller H, Drexel H. Bisphosphonates routine in prevention of post- transplant osteoporosis? J Bone Miner Res 2004; 19: 1919-1932. 34. Aczel S, Marte T, Drexel H. „Modulation der Blutfette durch körperliche Bewegung“ 33. Marte T, Drexel H. „Lipidsenker bei Hypertonie – Was besagt die Evidenz?“ 32. Drexel H. „Niedriges HDL: ein koronarere Risikofaktor“ J Kardiol 2004: 11[Supp 31. Drexel H. „Hohes HDL schützt vor Atherosklerose“. Medical Tribune 2004; 50. 30. Hoefle G, Holzmueller H, Drexel H. Alendronate versus calcitriol for prevention of bone loss after cardiac transplantation. N Engl J Med. 2004; 350:2306-2308. 29. Hoefle G, Saely CH, Tautermann G, Aczel S, Holzmueller H, Drexel H. Relationship between various measures of bone mineral density and vertebral fractures in cardiac transplant recipients. Swiss Med Wkly 2004; 134:215-220. 28. Saely CH, Marte T, Drexel H. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2004; 350:1150-1152. 27. Saely CH, Aczel S, Marte T, Langer P, Drexel H. Cardiovascular complications in Type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetic state. Diabetologia 2004; 47:145-146. 26. Hoefle G, Tautermann G, Saely CH, Drexel H. Sex hormone-binding globulin is negatively correlated with femoral bone mineral density in male cardiac transplant recipients. Wien Klin Wochenschr 2004; 116:170-175. 25. Hoefle G, Holzmueller H, Gouya G, Hergan K, Hubmann M, Langer P, Drexel H. Lower serum beta-CrossLaps in male cardiac transplant recipients treated without prednisolone. Transpl Int. 2003; 16:523-528. 24. Drexel H. The Role of Hyperlipidaemia in Peripheral Arterial Occlusive Disease. 23. Drexel H, Marte T. Gemeinsame Präventionsstrategien bei Herzinfarkt und Schlaganfall? Panvascular 2003; 4:6-9. 22. Drexel H. Kardiovaskuläre Primär-/Sekundärprävention – Biographischer Blick nach vorne. Diabetes Forum 2003; 3:33-35. 21. Lechleitner M, Drexel H. Diabetes und Lipide. Wien Med Wochenschr 2003; 153:469- 20. Zuber-Jerger I, Drexel H. Aphthous colitis induced by non-steroidal antirheumatic drugs. Swiss Med Wkly 2003; 11:133:544-545. 19. Drexel H. Expertenkommentar zur ELVA-Studie. Jatros 2002; 3:42. 18. Benzer W, Aczel S, Drexel H. A Clinical Practice Model to Estimate the Cost. Effectiveness of Lipid Lowering Therapy With Statins in Patients at Risk for Coronary Artery Disease. J Clin Basic Cardiol 2002; 5:179-182. 17. Geltner C, Lechleitner M, Föger B, Ritsch A, Drexel H, Patsch JR. Insulin improves fasting and postprandial lipemia in type 2 diabetes. Eur J Intern Med. 2002; 13:256-263. 16. Kuster G, Amann FW, Neuenschwander C, Drexel H. High Density-Lipoprotein Subfractions of Patients using Cardio-Selective Beta Blockers. Cardiovascular Drugs and Therapy 2002;16:127-131. 15. Drexel H. Lessons from the Hoorn Study: Schlüssiges Konzept der Diabetesprävention. Diabetes Forum 2001; 3/01. 14. Drexel H. Kardioprotektion bei Diabetes - Welche Bedeutung haben die Statine? 13. Tautermann G, Ruebsamen H, Beck M, Dertinger S, Drexel H. R116C Mutation of Cationic Trypsinogen in an Turkish Family with Recurrent Pancreatitis Illustrates Genetic Microheterogenity of Hereditary Pancreatitis. Digestion 2001; 61:226-232. 12. Wiederin TBJ, Krings T, Vonbank H, Hergan K, Peschina W, Fritsche H, Mathies R, Drexel H, Koppi S. MRI, Proton Magnetic Resonance Spectroscopy and Tcc-99m HMPAO SPECT in a Patient with Transient Global Amnesia. Klin Neuroradiol 2001; 11: 216-220. 11. Drexel H, Schmid HR, Follath F. Effects of Bisoprolol on Lipoprotein Cholesterol Subfractions and Apolipoproteins in Patients with Hypertension. Journal of Clinical and Basic Cardiology 2001; 4:57. 10. Drexel H. Experten-Meinungen. Update, Internationale Zeitschrift für ärztliche Fortbildung.Nr.20/September 2000. 9. Drexel H. Der multimorbide Patient. Ärztemagazin 21/2000, 27.Mai 2000. 8. Drexel H. Universum Innere Medizin, Ausgabe "Diabetologie", 02/2000. 7. Benzer W, Fritzsche H, Kargl M, Drexel H: Revascularization of residual viable myocardium improves left ventricular dysfunction in patients after myocardial infarction. Wien Klin Wochenschrift 1999; 111:636-642. 6. Drexel H, Gaul GB, Grimm G, Klein W, Kleemann L, Leisch F, Mlczoch J, Pichler M, Sailer S, Slany J, Steinbach K, Tragl KH, Mori M, Kuhn P: Secondary prevention following coronary intervention. Survey of 13 intervention centers in Austria. Wien Klin Wochenschrift 1999; 111:643. 5. Drexel H. Treatment of Dyslipidemia and Influence of Lipid-Lowering Therapy on Atherosclerotic Disease. Editorial; Critical Ischemia 1999. 4. Fuchs W, Wolber T, Wöss E, Neyer U, Drexel H. Leptospirose mit akutem Nierenversagen, schwerem Ikterus, disseminierten Blutungen und Xanthopsie. Schweiz Med Wochenschrift 1999; 129:847. 3. Benzer W, Bitschnau R, Gröchenig E, Aczel S, Drexel H: Regular physical activity and risk factors for coronary heart disease. Circulation 1998; 21:2356. 2. Dertinger SH, Dirschmid K, Vogel W, Drexel H: Immunosuppressive Therapy of Carbamazepine-induced Hypersensitivity Syndrome and Hepatitis. J Hepatol 1998; 28/2: 356-357. 1. Ritsch A, Drexel H, Amann FW, Pfeifhofer Ch, Patsch J. Deficiency of Cholesteryl Ester Transfer Protein: Description of the Molecular defect and the Dissociation of Cholesteryl Ester and Triglyceride Transport in Plasma. Arteriosclerosis and Thrombosis Vasc. Biol. 1997; 17:433-441.

Source: http://www.lkhf.at/redaktion/uploads/files/eabb2279e8c1ee8b01888deba7c0c05b/vivit-publikationsliste_bis_03_2010.pdf